Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Cullinan Oncology, LLC. (11/29/17). "Press Release: Cullinan Oncology Adds Industry Leaders to Board, Bringing Significant Business & Healthcare Acumen". Cambridge, MA.

Organisations Organisation Cullinan Oncology LLC
  Group Cullinan Oncology (Group)
  Organisation 2 Novartis AG (NYSE: NVS)
  Group Novartis (Group)
Products Product cancer drug
  Product 2 pharmaceutical
Index term Index term Cullinan Oncology–UBS: investment, 201710 financing round Series A totalling $150m incl co-lead investor UBS Oncology Impact Fund managed by MPM
Persons Person Ebeling, Thomas (UBS 201711 Standing Member of UBS Oncology Impact Fund former Novartis Pharma CEO)
  Person 2 Rosenberg, Tony (MPM Capital 201711 Managing Director before Novartis + Sandoz)
     


Cullinan Oncology, LLC, a company dedicated to significantly enhancing the standard of care in cancer by shepherding breakthrough science, announced today the appointment of Thomas Ebeling and Tony Rosenberg to its Board of Directors.

“We are fortunate to have both Thomas and Tony join the Cullinan board. Their collective experience in healthcare and beyond will be invaluable as we scale the company and build our pipeline of novel cancer therapies,” said Owen Hughes, Cullinan CEO.

Thomas Ebeling is a standing member of the UBS Oncology Impact Fund (OIF) managed by MPM Capital. He is also CEO of ProSiebenSat.1 Media SE, one of Europe’s largest mass media companies; a member of the supervisory board of Bayer AG; and a member of the advisory boards of Sivantos, a world leading hearing aid company, and GFK, a leading market research company. From 2000 to 2007, Thomas was CEO of the global Novartis pharmaceuticals business where, under his leadership, the company’s revenues more than doubled from $11B to nearly $23B. Before that, he was responsible for the leadership of the Novartis Nutrition division where he headed three business units.

“I’m excited to join Cullinan given the accelerating pace of scientific innovation in oncology,” stated Mr. Ebeling. “I look forward to working with this talented group to unlock the promise of new technologies and usher in the next wave of improved outcomes for those living with cancer.”

Tony Rosenberg is a managing director at MPM Capital where he is a board member at portfolio companies Clinical Ink, iOmx Therapeutics, Radius, and TriNetX. He is also an independent board member of argenx. Prior to MPM Capital, he was Global Head, M&A and Licensing at Novartis where he oversaw the Novartis portfolio transformation, a comprehensive set of transactions, to focus the company on its global businesses in innovative pharmaceuticals, eye care, and generics. Tony joined Novartis via its predecessor company Sandoz where he held diverse leadership positions in sales and marketing, business development and strategic planning.

“I’m delighted to join the board of directors of Cullinan Oncology,” said Mr. Rosenberg. “The combination of a world class management team and a truly innovative operational model will, I believe, lead to the development of real breakthroughs in cancer therapy and, most importantly, better outcomes for patients.”


About Cullinan

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, the company’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model. Cullinan is backed by the UBS Oncology Impact Fund (OIF) managed by MPM Capital, a worldwide leader in oncology investing, and F2 Ventures. For additional information, please visit www.cullinanoncology.com.


Contacts

Cullinan Oncology, LLC
Matt Burke, +1 603-315-0618
mattdavidburke@gmail.com

   
Record changed: 2018-02-27

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Cullinan Oncology (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top